Research analysts covering Immatics.
Recent press releases and 8-K filings for IMTX.
Immatics N.V. Provides Clinical Pipeline Updates for PRAME-Targeted Therapies
IMTX
Product Launch
New Projects/Investments
- Immatics provided updates on its PRAME-targeted clinical pipeline, which includes Anzu-cel (IMA203), IMA203CD8 (GEN2), and IMA402 (PRAME Bispecific).
- Anzu-cel (Wave #1) is currently in an ongoing Phase 3 SUPRAME trial for advanced melanoma, with interim and final data analysis expected in 2026. The Biologics License Application (BLA) submission is targeted for 1H 2027, and market launch is anticipated in 2H 2027.
- IMA203CD8 (Wave #2) is on track to complete dose escalation and determine its Recommended Phase 2 Dose (RP2D) in 2026, with efficacy readouts for the two highest dose levels also expected in 2026.
- IMA402 (Wave #3) is completing its Phase 1b dose expansion to determine the final RP2D in 2026. The company also plans to initiate additional Ph1b/Ph2 expansion cohorts and an IMA402/IMA401 combination study in squamous non-small cell lung cancer (sqNSCLC) in 2026.
Jan 12, 2026, 9:09 PM
Immatics N.V. Presents Updated Phase 1a Data for IMA203CD8 PRAME Cell Therapy
IMTX
New Projects/Investments
Guidance Update
- Immatics N.V. provided updated Phase 1a dose escalation data for its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors, with a data cutoff of October 27, 2025.
- The therapy demonstrated manageable tolerability in the 78 enrolled patients, with no Grade 5 IMA203CD8-related adverse events observed.
- Initial anti-tumor activity included a Confirmed Objective Response Rate (cORR) of 36% (23/64) and an Objective Response Rate (ORR) of 46% (32/69), with a median Duration of Response (mDOR) of 9.2 months at a median follow-up of 14 months.
- Dose escalation is ongoing, and the company is on track to determine the recommended Phase 2 dose (RP2D) in 2026, aiming to position IMA203CD8 for tumor-agnostic use in advanced PRAME cancers beyond melanoma.
Dec 11, 2025, 12:10 PM
Immatics presents IMA203CD8 PRAME Cell Therapy Phase 1a data
IMTX
New Projects/Investments
Product Launch
- Immatics N.V. announced updated Phase 1a dose escalation data for its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors on December 11, 2025.
- The therapy demonstrated manageable tolerability across all dose levels, with anticipated cytopenias and mostly Grade 1 to 2 cytokine release syndrome (CRS).
- Encouraging early clinical anti-tumor activity was observed, with an Objective Response Rate (ORR) of 46% (32/69) and a Disease Control Rate (DCR) of 84% (58/69) at week 6 in efficacy-evaluable patients as of October 27, 2025.
- A promising dose-dependent clinical signal was noted in ovarian carcinoma, supporting the strategy to position IMA203CD8 for advanced PRAME cancers beyond melanoma.
- Immatics expects to complete Phase 1a dose escalation and determine the Recommended Phase 2 Dose (RP2D) in 2026.
Dec 11, 2025, 12:00 PM
Immatics N.V. completes $125 million underwritten offering
IMTX
- Immatics N.V. announced and completed a $125 million underwritten offering of 12,500,000 ordinary shares at $10.00 per share on December 8, 2025.
- The gross proceeds from the offering are $125 million, with net proceeds of approximately $116.5 million after deducting underwriting discounts and expenses.
- The company intends to use the net proceeds to fund continued research and development of its pipeline, manufacturing, production, and commercialization of product candidates, and for working capital and other general corporate purposes.
Dec 8, 2025, 9:20 PM
Immatics Announces Third Quarter 2025 Financial Results and Business Update
IMTX
Earnings
CFO Change
New Projects/Investments
- Immatics reported a net loss of $59.3 million (€50.5 million) for the three months ended September 30, 2025, an increase from a net loss of $6.2 million (€5.3 million) in the prior year, with total revenue decreasing to $6.1 million (€5.2 million) from $59.4 million (€50.6 million) in Q3 2024 due to lower collaboration revenue.
- The company's cash and cash equivalents, along with other financial assets, totaled $505.8 million (€430.8 million) as of September 30, 2025, providing cash reach into 2H 2027.
- The Phase 3 SUPRAME trial for anzu-cel (IMA203) in advanced melanoma is ongoing, with interim and final analyses anticipated in 2026, and a Biologics License Application (BLA) submission planned for 1H 2027.
- Updated Phase 1b data for anzu-cel in metastatic uveal melanoma showed a clinical objective response rate (cORR) of 67% and a median duration of response (mDOR) of 11.0 months in 16 patients, leading to the initiation of a Phase 2 cohort.
- Immatics appointed Venkat Ramanan, Ph.D., as Chief Financial Officer on October 1, 2025, and Amie Krause as Chief People Officer on October 27, 2025.
Nov 17, 2025, 12:08 PM
Immatics N.V. reports updated Phase 1a clinical data for IMA402 and IMA401
IMTX
New Projects/Investments
- Immatics N.V. announced updated Phase 1a dose escalation data for its IMA402 PRAME Bispecific and IMA401 MAGEA4/8 Bispecific programs, with a data cutoff of September 26, 2025.
- The IMA402 PRAME Bispecific demonstrated favorable tolerability and a 30% confirmed objective response rate (cORR) across all indications in the recommended Phase 2 dose (RP2D) range, with all 6 confirmed objective responses ongoing.
- The IMA401 MAGEA4/8 Bispecific also showed favorable tolerability and achieved a 25% cORR in head and neck cancer and a 29% cORR in melanoma at doses of ≥1 mg.
- Phase 1a dose escalation is complete for both programs, and Phase 1b dose expansion for IMA402 has been initiated to determine the final RP2D, with a focus on melanoma and gynecologic cancers.
Nov 12, 2025, 12:19 PM
Immatics Announces Clinical Proof-of-Concept for TCR Bispecific Pipeline
IMTX
Product Launch
New Projects/Investments
- Immatics announced positive Phase 1a dose escalation data for its TCR Bispecifics, IMA402 PRAME Bispecific and IMA401 MAGEA4/8 Bispecific, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients.
- The IMA402 PRAME Bispecific achieved a 30% confirmed objective response rate (cORR) across all indications (6/20) at its recommended Phase 2 dose (RP2D) range, with 29% (4/14) in melanoma and 2/3 in ovarian carcinoma.
- The IMA401 MAGEA4/8 Bispecific showed a 25% cORR (2/8) in head and neck cancer and 29% cORR (2/7) in melanoma at doses of 1 mg or higher.
- Immatics is advancing IMA402 into Phase 1b dose expansion in 2026 for melanoma and gynecologic cancers, and plans to explore a combination of IMA402 with IMA401 in squamous non-small cell lung cancer.
Nov 12, 2025, 12:00 PM
Immatics N.V. highlights updated anzu-cel PRAME cell therapy data in metastatic uveal melanoma
IMTX
New Projects/Investments
- Immatics N.V. announced updated data from its Phase 1b clinical trial evaluating anzu-cel PRAME cell therapy in 16 patients with metastatic uveal melanoma, with a data cutoff of September 24, 2025.
- The trial demonstrated a confirmed objective response rate (cORR) of 67% (10/15) and a disease control rate (DCR) of 88% (14/16).
- Key durability metrics include a median duration of response (mDOR) of 11 months and a median progression-free survival (mPFS) of 8.5 months.
- Median overall survival (mOS) was not reached at a median follow-up of 14.3 months, with an OS rate of 71% at 12 months.
- Based on these promising clinical data, Immatics has initiated a Phase 2 cohort for anzu-cel in patients with metastatic uveal melanoma.
Oct 20, 2025, 2:30 PM
Immatics Highlights Anzu-cel PRAME Cell Therapy Data in Metastatic Uveal Melanoma
IMTX
New Projects/Investments
- Immatics N.V. (IMTX) announced updated Phase 1b clinical data for its anzu-cel PRAME cell therapy in 16 patients with metastatic uveal melanoma, presented at the ESMO 2025 Presidential Symposium.
- The therapy demonstrated strong anti-tumor activity, with a confirmed objective response rate (cORR) of 67%, a median duration of response (mDOR) of 11.0 months, and median overall survival (mOS) not reached at 14.3 months median follow-up.
- Anzu-cel maintained a favorable tolerability profile and showed anti-tumor activity across various metastases, including in patients previously treated with TCR-based therapies.
- Following these promising results, Immatics has initiated a Phase 2 cohort for approximately 30 uveal melanoma patients.
Oct 20, 2025, 2:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more